Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — H1 2023 Earnings Presentation
26 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, August 2023
Slide 1: 2023 Interim Results Presentation
2023 Interim Results Presentation Zylox-Tonbridge August 2023
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: Business Highlights
Business Highlights Financial Sales R&D industry leader of promoting 2 Number of NMPA 230 million RMB innovative ideas and techniques 8 registration approvals Revenue + 50.7% YOY Growth • Cooperate with KOLs to promote obtained in the first half of the concept and technique of trans- 2023 radial app
Slide 4: Financial Highlights
Financial Highlights Rapid Growth Efficiency Improvement
Slide 5: Commercialization of High-quality Products Triggered Rapid Revenue Growth
Commercialization of High-quality Products Triggered Rapid Revenue Growth Rapid Revenue Growth from 2021H1 to 2023H1 Overseas Revenue from 2021H1 to 2023H1 GPM stabilized as sales grew （ in million RMB ） （ in million RMB ） （ in million RMB ） Three-year CAGR：79% Three-year CAGR：85% Three-year CAGR：81
Slide 6: Neurovascular - Rapid Revenue Growth
Neurovascular - Rapid Revenue Growth Revenue of Neurovascular Products Main Source of Revenue （ in 000’ RMB） Thrombite® SilverSnake® % of Revenue: 60.0% 73.1% 72.1% Clot Retriever Intracranial Device Support Catheter 180,000 166,038 160,000 Phoenix® 49% Baiju® Detachable Coil Intracranial 140,000 Sy
Slide 7: Peripheral-vascular - Steady Revenue Growth
Peripheral-vascular - Steady Revenue Growth Revenue of Peripheral-vascular Products Main Source of Revenue （ in 000’ RMB） Drug Coated High Pressure PTA % of Revenue : 40.0% 26.9% 27.9% PTA Balloon Balloon Catheter Catheter 70,000 64,093 60,000 PTA Balloon Endovenous 56% Catheter Radiofrequency Ablat
Slide 8: Increasing Operating Expenses Level in Line with Business Development
Increasing Operating Expenses Level in Line with Business Development Selling and Distribution Expenses R&D Expenses Administrative Expenses % of Revenue : % of Revenue : % of Revenue : 94% 70% 57% 57% 54% 42% 33% 33% 22% 1 2 3 2021A 2022A 2023H1 2021A 2022A 2023H1 2021A 2022A 2023H1 Amount 100,599
Slide 9: With the Continuous Improvement of Sales Scale and Operational Efficiency, the Trend of Profits Emerged
With the Continuous Improvement of Sales Scale and Operational Efficiency, the Trend of Profits Emerged Other Non-operating Income and Expenses Adjusted Net Profit / (Loss )3 （ in 000’ RMB） （ in 000’ RMB ） 4 2021H1 2022H1 2023H1 2021A 2022A 2023H1 60,000 0 (5,522) (25,877) 3,638 (29,992) 50,000 4,57
Slide 10: Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years 2023H1 Cash Status Trade Receivables Turnover Trade Payables Turnover （ in 000’ RMB） （ Turnover Days ） （ Turnover Days ） 2,693,107 2,593,830 73 55 41 8,875 4,040 0.60 0.8 0.8 (22,353) (89,840) 2021A 2022A 2023H1 202
Slide 11: Sales and Marketing
Sales and Marketing The Pioneer in the Industry
Slide 12: Deeply Cultivate the Domestic Market and Build an Extensive Sales Network
Deeply Cultivate the Domestic Market and Build an Extensive Sales Network Steady Expansion of the Sales Marketing Team Supports the Rapid commercialization capabilities Rapid Development Numbers of Provincial Procurement Platforms that Newly Launched Products are Included into in last one year Numbe
Slide 13: Neurovascular Interventional Portfolio – Industry leader in advocating TRA
Neurovascular Interventional Portfolio – Industry leader in advocatnig the Concept and Technique of Trans-radial Approach (TRA) May 2023 • Held meetings and training sessions to provide physicians with opportunities of simulation operation and operation livestream Feb. 2023 • Supported Leading Physi
Slide 14: Neurovascular Interventional Portfolio – First to Launch TRA Access Products
Neurovascular Interventional Portfolio – First to Launch TRA Access Products and Corresponding Approach R-DAS （trans-Radial telescoping catheter technique with a Distal Access catheter and Simmons catheter） SilverSnake® DA + Simmons catheter / SilverSnake® Plus + Simmons catheter SilverSnake® DA Dis
Slide 15: Peripheral Vascular Interventional Portfolio – Professional Academic Marketing Strategy
Peripheral Vascular Interventional Portfolio – Professional Academic Marketing Strategy A Variety of Activities Leading One-stop Solution for VTE ( Venous Thromboembolism ) Domestic Leading One-stop VTE solution Provider Guiding Hundreds of Domestic Hospitals to Enhance the Concept of Venous Vascula
Slide 16: Peripheral Vascular Interventional Portfolio – Professional Academic Marketing Strategy
Peripheral Vascular Interventional Portfolio – Professional Academic Marketing Strategy Zylox Institute Widely Engage Healthcare Domestic Virtual Meetings to Exchange Professionals Surgical Skills Active Participation in Professional Academic Conferences CCI 2022 VINNOVA2023 SJVF 2023 CAVS 2023
Slide 17: Continued to Grow International Business and Further Enhanced our Brand Awareness
Continued to Grow International Business and Further Enhanced our Brand Awareness • In the first half of 2023, Overseas Revenue 6.23 million RMB，128.7% Growth Compared to 2022 • Commercialized in 19 countries overseas, including: Italy, Poland, Argentina, Turkey, Germany, South Africa, India and Fra
Slide 18: R&D
R&D Advance R&D with great efficiency steadily and innovatively
Slide 19: Robust R&D Pipelines Bolster the Long-term Growth
Robust R&D Pipelines Bolster the Long-term Growth Expect to launch 561 products 28 26 2 domestically in the upcoming 5 Neurovascular Peripheral-vascular Vascular Closure years Interventional Products Interventional Products Devices As of June,30 2023 2023H2 2024 2025 27 approved products +9 products
Slide 20: Key Products to be Launched within the Following Years
Key Products to be Launched within the Following Years 1 Second Generation Aspiration Catheter Flow Diverter Clot Retriever Device Peripheral Venous Peripheral Detachable Suture-mediated Stent System Fibered Embolization Coils Closure System Note: 1 Aspiration Catheter launched in the first half of
Slide 21: Efficient R&D and Manufacturing Platform Support Product Quality and Operational Efficiency
Efficient R&D and Manufacturing Platform Support Product Quality and Operational Efficiency Improving Steadily Expand Production Capacity R&D Efficiency Gradually Increase Scale Effect 25 NMPA registration approvals obtained in last 36 months Hangzhou R&D and 14 products in NMPA manufacturing center
Slide 22: 2023 Carry Out the Mission regardless Challenges
2023 Carry Out the Mission regardless Challenges Continue to Enhance Our Industry Leadership 1 Constantly expand product offering and accelerate innovation given the clinical needs • Acting proactively to the development of policies, we will deeply explore clinical needs and optimize product portfol
Slide 23: Appendix
APPENDIX Please refer to 2023 Interim Results Announcement for further information Click to download the 2023 Interim Results
Slide 24: Consolidated Statements of Profit or Loss
Consolidated Statements of Profit or Loss Year ended December 31 Six months ended June 30 % of % of % of % of RMB’000 2021 Revenue 2022 Revenue 2022 Revenue 2023 Revenue Revenue 177,912 100% 334,090 100% 152,743 100% 230,131 100% Cost of sales -46,031 -26% -81,421 -24% -37,266 -24% -59,485 -26% Gros
Slide 25: Consolidated Balance Sheet
Consolidated Balance Sheet As at RMB’000 31-Dec-22 30-Jun-23 Non-current assets Property, plant and equipment 290,243 426,167 Right-of-use assets 48,136 44,517 Intangible assets 9,637 10,331 Prepayments and other receivables 10,645 4,838 Financial assets at fair value through profit or loss 43,361 6
Slide 26: Consolidated Balance Sheet
Consolidated Balance Sheet As at RMB’000 31-Dec-22 30-Jun-23 Non-current liabilities Deferred revenue 7,974 Lease liabilities 7,459 4,956 Total non-current liabilities 7,459 12,930 Current liabilities Borrowings - 9000 Trade and other payables 126,652 151,420 Current income tax liabilities - 291 Con
Zylox-Tonbridge Medical Technology — H1 2023 Earnings Presentation on 6ix